Financial personality Vivian Tu warns against platforms marketing "prediction markets" as an investment class. She clarifies they are simply a modern form of gambling on outcomes, akin to sports betting, and will likely deplete wealth rather than build it.

It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

Tech-focused venture firms are finding their AI investment thesis fails in biotech. Despite massive paper profits in tech AI, their biotech AI portfolios show negative returns. This is because AI has yet to solve the complex biological bottlenecks of drug development, particularly in clinical trials, which remain slow and costly.

In high-stakes fields like pharma, AI's ability to generate more ideas (e.g., drug targets) is less valuable than its ability to aid in decision-making. Physical constraints on experimentation mean you can't test everything. The real need is for tools that help humans evaluate, prioritize, and gain conviction on a few key bets.

Extreme conviction in prediction markets may not be just speculation. It could signal bets being placed by insiders with proprietary knowledge, such as developers working on AI models or administrators of the leaderboards themselves. This makes these markets a potential source of leaked alpha on who is truly ahead.

VC Bruce Booth warns that investors without deep biotech R&D experience are backing AI-driven drug discovery companies at inflated valuations. He predicts many will 'get their hands burned' due to flawed assumptions about value creation in the sector.

While praised for aggregating the 'wisdom of crowds,' prediction markets create massive, unregulated opportunities for insider trading. Foreign entities are also using these platforms to place large bets, potentially to manipulate public perception and influence political outcomes.

Kai Ryssdal dismisses the reliability of prediction markets like Calci, calling them "black boxes" due to unknown bettors and potential manipulation. He cites a personal example where a dark horse candidate for Fed Chair saw his odds inexplicably spike on Calci without any supporting news, only to lose the appointment.

Contrary to popular belief, AI's role in drug discovery is marginal. Martin Shkreli argues the main hurdle is the billion-dollar, multi-year process of human clinical trials, an area where AI has little impact. The chemistry itself is a relatively solvable problem for experts.